

Alicante, 05 of October 2026

COMMUNICATION – MARKET NOTICE – FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.5.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter “Facephi” or “the Company”) hereby notifies the following:

At its meeting held on 7 September 2026, and following the resolution adopted by the Annual General Meeting of Shareholders held on 30 June 2026 to increase the number of members of the Board of Directors, the Company’s Board of Directors unanimously resolved to appoint Mr. Pablo Hurtado March by co-optation as a member of the Board of Directors, with the status of independent director. Due to an error, a previous communication to the market reported the appointment of Mr. Stéphane Gard, which has not yet taken place.

The appointment will remain in effect until the first General Meeting of Shareholders held following the resolution and will be submitted for ratification in accordance with applicable legal provisions.

Furthermore, the Board of Directors has approved the reorganisation of its committees. The Audit and Control Committee is composed of Mr. Pablo Reig Boronat, independent director, as Chair; Mr. Pablo Hurtado March, independent director, and Nice & Green, represented by Mr. Manuel Lanfossi, as members.

The Appointments and Remuneration Committee is composed of Mr. Pablo Hurtado March as Chair; Mr. Juan Alfonso Ortiz Company as Secretary; and Mr. Pablo Reig Boronat and NICE & GREEN, S.A., represented by Mr. Manuel Lanfossi, as members.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors